PRX-102 is indicated for the treatment of Fabry disease in adult patients. Credit: Pr Marie-Claire GUBLER, Paris, France / commons.wikimedia.org.

The European Commission (EC) has granted marketing authorisation to Chiesi Global Rare Diseases and Protalix BioTherapeutics’ PRX-102 (pegunigalsidase alfa) in the European Union (EU) to treat Fabry disease in adult patients.

The PEGylated enzyme replacement therapy (ERT), PRX-102 is a plant cell culture-expressed, and chemically modified recombinant version of the α‑Galactosidase‑A enzyme.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It was found to have a favourable circulatory half-life of about 80 hours, with targeted enzyme activity in organs that are affected by Fabry disease, in clinical trials.

Chiesi Global Rare Diseases head Giacomo Chiesi said: “People living with Fabry disease often perceive their disease as burdensome and still experience unmet medical needs.

“Our deepest gratitude to all patients and patient advocates who have stood shoulder-to-shoulder with clinical researchers, scientists, and regulators during the clinical development programme, providing the data needed for this approval.”

The authorisation from EC was based on the data obtained from a comprehensive clinical development programme, which was conducted in over 140 patients, who received treatment for up to 7.5 years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company stated that PRX-102 has been investigated in ERT-experienced and ERT-naïve patients, including in a head-to-head trial.

It showed non-inferior efficacy to agalsidase beta in controlling the kidney disease, as assessed by the estimated glomerular filtration rate (eGFR) decline.

Protalix BioTherapeutics president and CEO Dror Bashan said: “The European Commission’s approval of PRX-102 is a significant milestone for patients with Fabry disease and their families, providing a new therapeutic option.

“Based on solid results from our robust clinical programmes, PRX-102 has the potential to be widely used for many years to come.”